ArticleJournal for immunotherapy of cancer2024

Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China.

Wenyan Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.